≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback

Generalized pustular psoriasis

DOID EFO Endpoint Browser PheWeb

L12_PSORI_PUSTGEN

impetigo herpetiformis: An impetigo that is characterized as a form of severe pustular psoriasis occurring in pregnancy.

Suggest a new description

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

None

519870

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — L40.1
  • Hospital discharge: ICD-9 — 6961B
  • Hospital discharge: ICD-8 — 69610
  • Cause of death: ICD-10 — L40.1
  • Cause of death: ICD-9 — 6961B
  • Cause of death: ICD-8 — 69610

2 out of 7 registries used, show all original rules.

136

4. Check minimum number of events

None

136

5. Include endpoints

None

136

6. Filter based on genotype QC (FinnGen only)

130

Control definitions (FinnGen only)

Control exclude
L12_PAPULOSQUAMOUS

Extra metadata

Level in the ICD hierarchy
4
First used in FinnGen datafreeze
DF2
Parent code in ICD-10
L40
Name in latin
Psoriasis pustulosa generalisata

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population 983 481 487
Only index persons 740 384 356
Unadjusted period prevalence (%)
Whole population 0.01 0.01 0.01
Only index persons 0.01 0.01 0.01
Median age at first event (years)
Whole population 54.30 56.74 51.88
Only index persons 52.55 54.23 50.72

-FinnGen-

Key figures

All Female Male
Number of individuals 130 72 58
Unadjusted period prevalence (%) 0.03 0.03 0.03
Median age at first event (years) 52.37 50.72 54.42

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
136
Matched controls
1360
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
L40.1
ICD-10 Finland
Generalized pustular psoriasis
+∞
148.5
114
*
D05AX52
ATC
calcipotriol, combinations; topical
82.1
115.1
65
15
L40.0
ICD-10 Finland
Psoriasis vulgaris
439.8
85.0
77
*
D07XC01
ATC
betamethasone; topical
23.3
78.6
76
70
D05AX02
ATC
calcipotriol; topical
374.5
66.7
62
*
L04AX03
ATC
methotrexate; systemic
19.3
64.4
64
60
D05BB02
ATC
acitretin; oral
272.8
64.2
61
*
D07AD01
ATC
clobetasol; topical
13.3
52.7
73
109
L40.5
ICD-10 Finland
Arthropathic psoriasis
+∞
45.4
41
*
D07AC01
ATC
betamethasone; topical
15.2
44.7
113
333
E000003, ,
ATC
21.9
44.3
36
22
E000001, ,
ATC
10.3
42.8
75
145
M07.3*L40.5
ICD-10 Finland
Other psoriatic arthropathies
+∞
41.9
38
*
E0000UV, ,
ATC
14.4
39.1
116
390
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
10.9
36.6
49
67
319
Kela drug reimbursment
Adalimumab, brodalumab, certolizumab pegol, etanercept, guselkumab, infliximab, ixekizumab, risankizumab, sekukinumab and ustekinumab (skin psoriasis)
+∞
36.1
33
*
D05AX03
ATC
calcitriol; topical
435.1
34.5
33
*
L40.9
ICD-10 Finland
Psoriasis, unspecified
224.3
34.5
34
*
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
9.3
32.6
50
80
NK4XE
NOMESCO Finland
Joint ultrasound examination not elsewhere classified
11.2
26.1
31
35
A07EC01
ATC
sulfasalazine; oral, rectal
9.1
25.1
36
52
D07AB02
ATC
hydrocortisone butyrate; topical
5.9
23.9
78
254
134
Kela drug reimbursment
General erythroderma
274.3
23.4
23
*
L40.8
ICD-10 Finland
Other psoriasis
260.1
22.3
22
*
D07AC13
ATC
mometasone; topical
5.5
22.2
76
254
L04AB04
ATC
adalimumab; parenteral
36.9
21.5
27
9
L01BA01
ATC
methotrexate; systemic
22.2
20.7
30
17
L40.3
ICD-10 Finland
Pustulosis palmaris et plantaris
86.5
20.4
22
*
281
Kela drug reimbursment
Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab and tocilizumab
23.7
19.1
27
14
313
Kela drug reimbursment
Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab, tocilizumab and ustekinumab (rheumatoid diseases)
22.1
18.7
27
15
TNX10
NOMESCO Finland
Arthrocentesis, unspecified region, unspecified region
8.2
18.2
27
40
D07AB08
ATC
desonide; topical
6.0
17.9
39
86
L04AD01
ATC
ciclosporin; systemic
30.7
16.2
21
8
E000002, ,
ATC
5.8
15.7
34
74
TQW80
NOMESCO Finland
Local dermatologic skincare
21.6
15.3
22
12
L04AA01
ATC
[U] ciclosporin
64.2
15.2
17
*
M07.3
ICD-10 Finland
Other psoriatic arthropathies
+∞
13.8
13
*
L04AC10
ATC
secukinumab; parenteral
154.8
13.7
14
*
L27.0
ICD-10 Finland
Generalized skin eruption due to drugs and medicaments
154.8
13.7
14
*
L30.9
ICD-10 Finland
Dermatitis, unspecified
4.2
13.3
47
152
H02AB06
ATC
prednisolone; systemic
4.0
13.2
93
479
6961A
ICD-9 Finland
Psoriasis and similar disorders, Other psoriasis[PSORIASIS VULGARIS]
+∞
12.7
12
*
L04AB01
ATC
etanercept; parenteral
24.0
12.4
17
8
6961B
ICD-9 Finland
Psoriasis and similar disorders, Other psoriasis[PSORIASIS PUSTULARIS]
+∞
11.6
11
*
L04AC05
ATC
ustekinumab; parenteral
+∞
11.6
11
*
M07.0*L40.5
ICD-10 Finland
Distal interphalangeal psoriatic arthropathy
+∞
11.6
11
*
L40
ICD-10 Finland
Psoriasis
38.7
11.5
14
*
69610
ICD-8 Finland
Psoriasis and similar disorders, Psoriasis pustulosa
+∞
10.5
10
*
D02AE01
ATC
carbamide; topical
5.5
9.9
21
44
ND2AA
NOMESCO Finland
Hand and fingers X-ray examination
4.5
9.8
27
71
L04AC13
ATC
ixekizumab; parenteral
107.2
9.5
10
*
D07BA04
ATC
hydrocortisone and antiseptics; topical
4.8
9.3
23
55
D07BB04
ATC
hydrocortisone butyrate and antiseptics; topical
4.0
9.3
31
94
WXQ27
NOMESCO Finland
UVB narrow spectrum light therapy
39.5
9.2
11
*
NH3AA
NOMESCO Finland
Foot and toes X-ray examination
4.6
9.0
24
61
E000006, ,
ATC
5.5
8.6
18
37
H02AB07
ATC
prednisone; oral
3.8
8.6
31
99
L04AA13
ATC
[U] leflunomide
11.9
8.5
15
14
69619
ICD-8 Finland
Psoriasis and similar disorders, Psoriasis alia sive NUD (vulgaris)
+∞
8.4
8
*
6960A
ICD-9 Finland
Psoriasis and similar disorders, Psoriatic arthropathy
+∞
8.4
8
*
L04AA11
ATC
[U] etanercept
+∞
8.4
8
*
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.8
7.8
84
497
S91
ICPC
Psoriasis
47.8
7.8
9
*
D02AX
ATC
Other emollients and protectives
9.8
7.8
15
17
D05AA
ATC
Tars
+∞
7.4
7
*
L04AC21
ATC
bimekizumab; systemic
+∞
7.4
7
*
D01AC20
ATC
imidazoles/triazoles in combination with corticosteroids; topical
2.9
7.2
44
193
E000007, ,
ATC
6.3
7.1
18
32
D07AA02
ATC
hydrocortisone; topical
3.2
6.7
32
121
EB1HA
NOMESCO Finland
Panorama tomography of teeth and jaws or similar X-ray examination
2.5
6.3
66
375

TimeCodeWAS

↥

TODO / Current known limitations:

  • Only showing the top 500 codes, because showing all (sometimes 20k) makes the page too slow.
  • Legend / how to read the glyphs.
  • Proper column names.
  • Show details (e.g. Fisher or Chi-square test, N cases and N controls) when clicking on a row.
  • Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
  • Download CSV not working.
  • No filters and sorters.
  • Limited amount of endpoints with TimeCodeWAS data.
  • Cross-links to Risteys lab test pages for lab test codes.
OMOP Concept
ln(OR) -5y
ln(OR) -1y
ln(OR) -1m
ln(OR) d0
ln(OR) +1m
ln(OR) +1y
ln(OR) +5y
MCC -5y
MCC -1y
MCC -1m
MCC d0
MCC +1m
MCC +1y
MCC +5y
Psoriasis vulgaris
L40.0 (45543370)
Other psoriatic arthropathies
M07.3*L40.5 (2000503010)
Pustulosis palmaris et plantaris
L40.3 (45591634)
calcitriol; ointment
D05AX03 (21602040)
acitretin; oral
D05BB02 (21602051)
Generalized pustular psoriasis
L40.1 (45552978)
Arthropathic psoriasis
L40.5 (45557703)
Biopsy of skin and subcutaneous tissue
TQX10 (2001310152)
Adalimumab, brodalumab, certolizumab pegol, etanercept, guselkumab, infliximab, ixekizumab, risankizumab, sekukinumab and ustekinumab (skin psoriasis)
319 (2001600280)
calcipotriol; ointment
D05AX02 (21602039)
clobetasol
D07AD01 (21602141)
Body height measure
50373000 (4177340)
Body mass index
60621009 (4245997)
Psoriasis
L40 (45577035)
hydrocortisone
A07EA02 (21600654)
betamethasone
A07EA04 (21600656)
hydrocortisone
C05AA01 (21601608)
betamethasone
C05AA05 (21601610)
imidazoles/triazoles in combination with corticosteroids
D01AC20 (21601936)
hydrocortisone
D07AA02 (21602102)
hydrocortisone butyrate
D07AB02 (21602106)
hydrocortisone buteprate
D07AB11 (21602115)
combinations of corticosteroids
D07AB30 (21602118)
betamethasone
D07AC01 (21602120)
hydrocortisone aceponate
D07AC16 (21602135)
combinations of corticosteroids
D07XB30 (21602188)
hydrocortisone
S02BA01 (21605166)
betamethasone
S02BA07 (21605169)
betamethasone
S03BA03 (21605203)
Supplier / Service Provider
OMOP5117446 (33004)
Clinical & Laboratory Dermatological Immunology Physician
207NI0002X (38003841)
Internal Medicine
11 (38004456)
Rheumatology
66 (38004491)
Inpatient Hospital
21 (8717)
Inpatient Visit
IP (9201)
Outpatient Visit
OP (9202)
methotrexate
L01BA01 (21601423)
methotrexate; oral, parenteral
L04AX03 (21603929)
other preparations, combinations; ointment
C05AX03 (21601631)
prednisolone; oral, parenteral
H02AB06 (21602734)
prednisolone
A07EA01 (21600653)
Neutrophils [#/volume] in Blood by Automated count
751-8 (3013650)
mometasone
D07AC13 (21602132)
cefalexin; oral
J01DB01 (21602870)
Pharmacy visit
OMOP4822462 (581458)
Case Management Agency
251B00000X (38004193)

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
49
153
4.44
14.66
1.4
1.3
465.45
607.00
titre
0.21
11
40
84
401
3.86
13.43
16.5
7.1
—
—
—
0
0
102
634
3.44
9.31
20.1
7.2
0.20
0.19
e9/l
0.52
97
554
94
562
3.18
9.08
19.7
6.9
58.69
57.69
%
0.38
94
536
21
49
4.89
8.76
1.8
1.2
—
—
—
0
0
25
86
3.34
6.12
1.2
1.5
—
—
—
0
0
26
97
3.08
5.56
7.1
4.8
0.25
0.50
%
—
8
35
32
135
2.79
5.50
2.1
1.8
—
—
—
0
0
26
99
3.01
5.36
7.6
4.8
0.13
0.17
%
—
8
35
26
106
2.80
4.73
7.6
4.7
0.50
0.81
%
—
8
43
13
27
5.21
4.63
1.8
1.7
16100.25
16485.00
e6/l
—
8
19
41
211
2.35
4.63
1.3
1.8
—
—
—
0
0
36
175
2.44
4.61
1.3
1.5
—
—
—
0
0
37
187
2.34
4.32
1.3
1.3
1.40
8.52
u/ml
—
6
66
73
486
2.08
4.25
7.3
4.4
82.40
63.22
e6/l
0.12
50
348
92
669
2.16
4.23
6.2
4.2
0.00
10.75
estimate
0.50
21
151
31
146
2.45
4.22
1.2
1.6
—
—
—
0
0
25
106
2.66
4.21
8.5
5.0
0.00
0.31
%
—
5
36
91
662
2.13
4.14
6.2
4.1
0.00
0.00
estimate
-0.00
21
145
86
615
2.08
4.06
9.5
8.2
1.21
1.21
mmol/l
0.29
76
530
10
18
5.90
4.06
1.5
1.6
—
—
—
0
0
30
143
2.41
3.97
1.4
1.4
—
—
—
0
0
76
524
2.02
3.92
5.3
3.9
6.01
6.21
ph
0.93
40
300
10
20
5.31
3.77
1.5
1.4
—
—
—
0
0
51
310
2.03
3.69
3.0
2.1
3.29
2.87
mg/l
0.42
43
266
91
678
2.03
3.68
6.2
4.2
0.00
0.00
estimate
-0.00
19
137
61
396
1.98
3.67
4.4
4.0
13.43
7.55
mg/mmol
0.45
42
255
48
289
2.02
3.55
6.5
4.0
—
0.00
—
0
5
61
412
1.87
3.15
3.6
3.3
7.72
7.70
mmol/l
0.01
54
351
44
268
1.95
3.09
9.4
5.4
—
—
—
0
0
37
212
2.02
3.09
1.5
1.3
28.09
28.13
iu/ml
—
10
71
27
141
2.14
2.86
6.7
7.6
7.40
7.42
ph
0.40
16
87
57
387
1.81
2.83
15.1
7.3
—
—
—
0
0
41
254
1.88
2.70
1.5
1.4
3.18
2.39
g/l
0.79
24
142
22
110
2.19
2.59
2.9
3.5
65.35
73.52
e9/l
0.55
15
79
56
387
1.76
2.57
3.7
3.3
81.71
47.66
mg/l
0.35
38
255
53
364
1.75
2.47
3.9
3.4
—
—
—
0
0
111
941
1.98
2.46
15.4
8.7
76.84
81.06
u/l
0.61
106
886
15
65
2.47
2.41
1.9
2.6
—
—
—
0
0
76
580
1.70
2.39
15.3
12.9
1.17
1.24
inr
0.62
65
492
60
436
1.67
2.23
5.8
3.7
16.97
52.13
e6/l
1.62
48
337
70
531
1.66
2.19
2.7
2.1
87.13
94.42
pmol/l
0.74
47
279
51
357
1.69
2.17
5.4
3.4
—
0.00
—
0
6
53
375
1.68
2.16
5.5
3.5
0.72
0.31
e6/l
0.29
41
279
23
127
1.98
2.10
3.1
2.0
0.00
0.00
estimate
—
6
29
43
290
1.71
2.09
5.8
4.4
1.02
1.02
kg/l
1.07
33
190
53
379
1.65
2.06
5.4
4.1
7.40
7.40
ph
0.17
39
273
5
11
4.67
1.96
2.0
5.2
309.60
449.00
mg
—
5
11
40
277
1.63
1.73
1.5
1.2
13.00
1.40
u/ml
—
10
60
49
359
1.57
1.67
6.2
4.8
—
—
—
0
0
15
77
2.07
1.67
3.1
3.7
—
—
—
0
0
51
379
1.55
1.63
5.5
4.0
0.00
0.00
estimate
-0.00
20
135
6
20
3.09
1.60
3.7
2.1
4.32
4.24
e9/l
—
6
20
5
15
3.42
1.53
1.4
4.2
—
—
—
0
0
13
66
2.07
1.49
2.1
2.1
0.00
0.00
estimate
—
5
22
7
28
2.58
1.47
1.1
3.2
9.20
9.40
pmol/l
—
7
28
62
493
1.47
1.40
2.4
2.0
—
—
—
0
0
42
310
1.51
1.36
2.2
2.3
1.79
1.59
mg/l
0.12
33
255
19
116
1.74
1.30
8.7
8.7
—
—
—
0
0
27
183
1.59
1.26
2.1
2.1
—
—
—
0
0
61
494
1.43
1.21
2.3
2.1
1.39
1.34
mmol/l
0.31
51
403
8
38
2.17
1.20
1.1
1.4
—
—
—
0
0
20
128
1.66
1.16
1.4
1.5
—
—
—
0
0
8
40
2.06
1.14
1.1
1.4
—
—
—
0
0
8
40
2.06
1.14
1.1
1.4
—
—
—
0
0
62
509
1.40
1.12
5.8
4.1
0.00
0.00
estimate
-0.00
17
116
29
206
1.52
1.11
5.0
3.5
1.43
1.61
e6/l
0.08
15
108
8
41
2.01
1.11
1.1
1.4
—
—
—
0
0
8
41
2.01
1.11
1.1
1.4
—
—
—
0
0
9
45
2.07
1.07
1.6
1.2
—
—
—
0
0
16
99
1.70
1.05
1.3
1.1
—
—
—
0
0
21
140
1.59
1.05
3.0
4.7
7.37
7.39
ph
0.50
14
86
0
30
0.00
0.98
0.0
1.6
—
—
—
0
0
33
248
1.44
0.96
5.5
3.6
902.76
103.91
ng/l
0.49
25
196
20
135
1.56
0.96
1.7
1.3
—
—
—
0
0
122
1145
1.64
0.94
34.3
17.7
19.50
23.53
mg/l
1.23
112
964
6
31
1.98
0.85
3.8
1.9
57.67
57.77
%
—
6
31
6
31
1.98
0.85
1.7
1.1
—
—
—
0
0
47
383
1.35
0.85
4.4
3.7
0.00
0.00
estimate
-0.00
17
110
22
158
1.47
0.81
3.5
2.3
262.78
137.42
ug/g
0.77
22
130
15
99
1.58
0.79
4.9
3.5
—
—
—
0
0
10
60
1.72
0.74
21.5
6.4
—
—
—
0
0
13
86
1.57
0.69
3.7
3.3
—
—
—
0
0
5
28
1.81
0.67
3.0
3.0
—
—
—
0
0
6
101
0.58
0.65
5.2
2.7
5.25
6.23
ug/l
—
6
89
8
50
1.64
0.62
1.4
2.8
—
—
—
0
0
118
1120
1.40
0.62
5.8
5.3
6.06
5.92
mmol/l
0.50
112
1030
0
20
0.00
0.61
0.0
3.0
—
2.97
—
0
20
10
64
1.61
0.60
1.2
1.1
—
—
—
0
0
8
121
0.64
0.58
1.4
1.5
—
—
—
0
0
6
37
1.65
0.56
1.3
1.4
0.27
0.24
g/l
—
6
37
6
37
1.65
0.56
1.3
1.4
1.17
1.11
g/l
—
6
37
9
59
1.56
0.56
2.0
1.9
—
—
—
0
0
114
1085
1.31
0.51
5.6
4.3
1.35
1.27
mmol/l
0.78
109
998
22
174
1.32
0.49
1.4
1.3
—
—
—
0
0
7
49
1.45
0.46
2.3
5.7
1.73
1.50
mg/l
—
7
42
29
241
1.26
0.45
1.8
1.9
416.74
454.55
pmol/l
0.29
23
202
8
57
1.43
0.43
4.9
3.5
36.98
36.92
°c
—
8
57
112
1071
1.26
0.42
6.0
5.4
2.10
1.93
mu/l
0.60
107
978
0
15
0.00
0.41
0.0
1.1
—
—
—
0
0
117
1125
1.29
0.41
6.1
5.2
1.41
1.46
mmol/l
0.71
112
1039
0
17
0.00
0.41
0.0
1.1
—
—
—
0
0
0
17
0.00
0.41
0.0
1.1
—
—
—
0
0
12
92
1.33
0.33
5.3
3.7
—
—
—
0
0
95
903
1.17
0.33
5.2
4.4
14.82
14.88
pmol/l
0.07
90
812
117
1132
1.24
0.32
6.8
5.3
4.46
4.61
mmol/l
0.81
112
1053
10
129
0.76
0.29
3.8
2.8
33.80
31.81
u/l
—
10
103
113
1093
1.20
0.29
8.4
6.6
41.17
39.61
mmol/mol
1.07
107
1033
119
1158
1.22
0.27
7.1
6.0
2.65
2.70
mmol/l
0.19
114
1074
60
562
1.12
0.23
4.9
3.0
—
—
estimate
—
0
0
5
41
1.23
0.22
1.0
1.2
—
—
—
0
0
0
11
0.00
0.21
0.0
1.4
—
211.55
—
0
11
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.1
—
1.77
—
0
8
0
14
0.00
0.20
0.0
1.1
—
4.14
—
0
8
14
118
1.21
0.20
3.2
2.7
0.23
0.21
g/l
0.19
14
111
7
62
1.14
0.17
1.3
1.2
—
—
—
0
0
11
94
1.19
0.13
1.3
1.5
—
—
—
0
0
22
241
0.90
0.13
2.7
3.2
0.65
0.82
ug/l
0.57
13
156
38
403
0.92
0.12
6.1
5.7
1.88
2.26
ug/l
0.29
33
353
48
500
0.94
0.09
5.9
4.3
27.46
38.49
ng/l
0.59
39
366
16
146
1.11
0.08
8.2
4.6
3.46
39.08
ug/l
0.63
16
117
8
74
1.09
0.07
1.3
3.6
4.50
4.56
pmol/l
—
8
67
8
75
1.07
0.07
2.9
3.0
0.60
0.59
%
—
8
75
8
77
1.04
0.07
2.9
3.0
1.25
1.25
%
—
8
77
125
1238
1.12
0.07
50.1
26.2
91.92
91.21
fl
1.01
125
1229
17
158
1.09
0.06
1.4
1.3
—
—
—
0
0
12
109
1.11
0.06
4.5
2.4
6.07
6.07
ph
—
7
66
125
1239
1.11
0.06
50.8
26.4
132.26
134.65
g/l
0.93
125
1230
125
1239
1.11
0.06
50.1
26.1
30.26
30.34
pg
0.20
125
1230
125
1239
1.11
0.06
51.1
26.5
40.15
40.22
%
0.06
125
1230
12
110
1.10
0.05
1.8
1.3
—
—
—
0
0
38
390
0.96
0.03
4.7
2.7
—
—
—
0
0
122
1214
1.05
0.00
42.8
22.2
79.45
78.12
umol/l
0.12
122
1204
32
326
0.98
0.00
1.3
1.4
—
—
—
0
0
47
464
1.02
0.00
3.6
3.4
—
—
—
0
0
43
432
0.99
0.00
4.5
4.0
—
—
—
0
0
119
1188
1.01
0.00
26.7
15.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.5
—
—
—
0
0
0
8
0.00
0.00
0.0
2.4
—
3.75
—
0
8
0
6
0.00
0.00
0.0
3.5
—
1.63
—
0
6
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
7
77
0.90
-0.00
1.4
1.3
—
—
—
0
0
5
53
0.94
-0.00
3.6
1.7
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
57.60
—
0
5
0
5
0.00
-0.00
0.0
1.0
—
132.60
—
0
5
6
62
0.97
-0.00
5.5
3.4
24.15
711.29
u/ml
—
6
51
0
5
0.00
-0.00
0.0
2.0
—
244.16
—
0
5
0
7
0.00
-0.00
0.0
1.0
—
8.91
—
0
7
0
5
0.00
-0.00
0.0
1.6
—
11.76
—
0
5
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
48.40
—
0
5

Mortality – FinRegistry

↥

Association

Association between endpoint L12_PSORI_PUSTGEN and mortality.

Females

Parameter HR [95% CI] p-value
L12_PSORI_PUSTGEN 2.109 [1.55, 2.87] < 0.001
Birth year 0.988 [0.98, 1.0] 0.011

During the follow-up period (1.1.1998 — 31.12.2019), 84 out of 289 females with L12_PSORI_PUSTGEN died.

Males

Parameter HR [95% CI] p-value
L12_PSORI_PUSTGEN 2.046 [1.29, 3.24] 0.002
Birth year 0.988 [0.98, 1.0] 0.01

During the follow-up period (1.1.1998 — 31.12.2019), 89 out of 268 males with L12_PSORI_PUSTGEN died.

Mortality risk

Mortality risk for people of age

years, who have L12_PSORI_PUSTGEN.

N-year risk Females Males
1 0.185% 0.352%
5 0.897% 2.262%
10 2.342% 5.795%
15 4.631% 11.36%
20 8.298% 18.627%

Relationships between endpoints

↥

Index endpoint: L12_PSORI_PUSTGEN – Generalized pustular psoriasis

GWS hits: -

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data